Comparison 1.
PARP inhibitors versus other treatments or placebo
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Overall survival | 3 | Hazard Ratio (Random, 95% CI) | Subtotals only | |
| 1.1 PARP inhibitor versus other monotherapy | 1 | 97 | Hazard Ratio (Random, 95% CI) | 0.82 [0.00, 211083.92] |
| 1.2 PARP inhibitor versus placebo/NFT (in addition to conventional chemo) | 1 | 162 | Hazard Ratio (Random, 95% CI) | 1.17 [0.79, 1.74] |
| 1.3 PARP inhibitor versus placebo (as maintenance) | 1 | 264 | Hazard Ratio (Random, 95% CI) | 0.94 [0.63, 1.40] |
| 2 Overall survival (platinum‐sensitive only) | 2 | 426 | Hazard Ratio (Random, 95% CI) | 1.05 [0.79, 1.39] |
| 2.1 PARP inhibitor versus placebo/NFT (in addition to conventional chemo) | 1 | 162 | Hazard Ratio (Random, 95% CI) | 1.17 [0.79, 1.74] |
| 2.2 PARP inhibitor versus placebo (as maintenance) | 1 | 264 | Hazard Ratio (Random, 95% CI) | 0.94 [0.63, 1.40] |
| 3 Progression‐free survival | 4 | Hazard Ratio (Random, 95% CI) | Subtotals only | |
| 3.1 PARP inhibitor versus other monotherapy | 1 | 97 | Hazard Ratio (Random, 95% CI) | 0.88 [0.51, 1.52] |
| 3.2 PARP inhibitor versus placebo/NFT (in addition to conventional chemo) | 2 | 237 | Hazard Ratio (Random, 95% CI) | 0.72 [0.37, 1.43] |
| 3.3 PARP inhibitor versus placebo (as maintenance) | 1 | 264 | Hazard Ratio (Random, 95% CI) | 0.35 [0.25, 0.49] |
| 4 Progression‐free survival (platinum‐sensitive only) | 2 | 426 | Hazard Ratio (Random, 95% CI) | 0.42 [0.29, 0.60] |
| 4.1 PARP inhibitor versus placebo/NFT (in addition to conventional chemo) | 1 | 162 | Hazard Ratio (Random, 95% CI) | 0.51 [0.34, 0.77] |
| 4.2 PARP inhibitor versus placebo (as maintenance) | 1 | 264 | Hazard Ratio (Random, 95% CI) | 0.35 [0.25, 0.49] |
| 5 Objective response rate (RECIST) (no response) | 4 | 434 | Risk Ratio (IV, Random, 95% CI) | 0.90 [0.82, 0.99] |
| 5.1 PARP inhibitor versus other monotherapy | 1 | 97 | Risk Ratio (IV, Random, 95% CI) | 0.88 [0.70, 1.10] |
| 5.2 PARP inhibitor versus placebo/NFT (in addition to conventional chemo) | 2 | 232 | Risk Ratio (IV, Random, 95% CI) | 0.82 [0.57, 1.19] |
| 5.3 PARP inhibitor versus placebo (as maintenance) | 1 | 105 | Risk Ratio (IV, Random, 95% CI) | 0.92 [0.82, 1.03] |
| 6 Severe adverse events | 4 | Risk Ratio (IV, Random, 95% CI) | Subtotals only | |
| 6.1 Nausea (G3‐4) | 4 | 592 | Risk Ratio (IV, Random, 95% CI) | 1.23 [0.33, 4.60] |
| 6.2 Diarrhoea (G3‐4) | 4 | 592 | Risk Ratio (IV, Random, 95% CI) | 0.53 [0.15, 1.90] |
| 6.3 Vomiting (G3‐4) | 4 | 592 | Risk Ratio (IV, Random, 95% CI) | 1.42 [0.25, 8.10] |
| 6.4 Stomatitis (any grade) | 3 | 503 | Risk Ratio (IV, Random, 95% CI) | 0.44 [0.02, 10.15] |
| 6.5 Anaemia (G3‐4) | 4 | 592 | Risk Ratio (IV, Random, 95% CI) | 2.15 [0.89, 5.21] |
| 6.6 Neutropenia (G3‐4) | 2 | 220 | Risk Ratio (IV, Random, 95% CI) | 0.59 [0.09, 3.98] |
| 6.7 Other (G3‐4) | 3 | 483 | Risk Ratio (IV, Random, 95% CI) | 1.06 [0.16, 6.98] |
| 6.8 Any SAE | 1 | 156 | Risk Ratio (IV, Random, 95% CI) | 1.14 [0.89, 1.47] |
| 7 Adverse event during maintenance (any grade) | 2 | Risk Ratio (IV, Random, 95% CI) | Subtotals only | |
| 7.1 Nausea | 2 | 385 | Risk Ratio (IV, Random, 95% CI) | 3.82 [0.85, 17.22] |
| 7.2 Anaemia | 2 | 385 | Risk Ratio (IV, Random, 95% CI) | 2.30 [0.87, 6.08] |
| 7.3 Fatigue | 2 | 385 | Risk Ratio (IV, Random, 95% CI) | 1.35 [1.02, 1.78] |
| 8 Adverse event during maintenance (grade 3/4) | 2 | Risk Ratio (IV, Random, 95% CI) | Subtotals only | |
| 8.1 Nausea | 2 | 385 | Risk Ratio (IV, Random, 95% CI) | 4.21 [0.48, 36.69] |
| 8.2 Anaemia | 2 | 385 | Risk Ratio (IV, Random, 95% CI) | 5.26 [1.19, 23.20] |
| 8.3 Fatigue | 2 | 385 | Risk Ratio (IV, Random, 95% CI) | 2.12 [0.67, 6.71] |
| 9 Any adverse event during maintenance (any grade) | 2 | 385 | Risk Ratio (IV, Random, 95% CI) | 1.16 [0.94, 1.42] |
| 10 Any adverse event during maintenance (grade 3/4) | 2 | 385 | Risk Ratio (IV, Random, 95% CI) | 1.74 [1.22, 2.49] |